CKD 610
Latest Information Update: 05 Sep 2007
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in South Korea (unspecified route)
- 06 Jun 2000 New profile
- 06 Jun 2000 Preclinical development for Cancer in South Korea (Unknown route)